A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome

Archives of Internal Medicine

Volumn 158, Issue 8, 1998, Pages 908-914

  Petcrson, Phillip K ^a,c   Pheley, Alfred ^a   Schrocppel, Jill ^a   Schenck, Carlos ^a,c   Marshall, Paul ^a   Kind, Allan ^b   Haugland, J Mark ^b   Lambrecht, Lawrence J ^a   Swan, Suzanne ^a,c   Goldsmith, Steven ^a,c  

^a HENNEPIN COUNTY MEDICAL CENTER   (United States)

^b PARK NICOLLET CLINIC   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDROCORTISONE; FLUDROCORTISONE ACETATE; PLACEBO;

ADULT; ANXIETY NEUROSIS; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL DISEASE; HEADACHE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; THORAX DISEASE;

ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FATIGUE SYNDROME, CHRONIC; FEMALE; FLUDROCORTISONE; HEART RATE; HUMANS; MINERALOCORTICOIDS; NOREPINEPHRINE; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0032571803     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.8.908     Document Type: Article

References (28)

1. Holmes GP, Kaplan JE, Gantz NM, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med. 1988;108:387-389.
2. Fukuda K, Straus SE, Hickie I, et al. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann intern Med. 1994;121:953-959.
3. Komaroff AL, Fagioli LR, Doolittle TH, et al. Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups. Am J Med. 1996;101:281-290.
4. Buchwald D, Pearlman T, Umali J, Schmaling K, Katon W. Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals. Am J Med. 1996;101:364-370.
5. Vercoulen JHMM, Swanink CMA, Fennis JFM, Galama JMD, van den Meer JWM, Bleijenberg G. Prognosis in chronic fatigue syndrome: a prospective study on the natural course. J Neurol Neurosurg Psychiatry. 1996;60:489-494.
6. Hirata-Dulas CAI, Halstenson CE, Peterson PK. Medical therapy of chronic fatigue syndrome. In: Straus S, ed. Chronic Fatigue Syndrome. New York, NY: Marcel Dekker; 1994:387-404.
7. Straus SE, Dale JK, Tobi M, et al. Acyclovir treatment of the chronic fatigue syndrome. N Engl J Med. 1988;319:1692-1698.
8. Lloyd A, Hickie I, Wakefield D, Boughton C, Dwyer J. A double-blind, placebo-controlled trial of intravenous immunoglobulin therapy in patients with chronic fatigue syndrome. Am J Med. 1990;89:561-568.
9. Peterson PK, Shepard J, Macres M, et al. A controlled trial of intravenous immunoglobulin G in chronic fatigue syndrome. Am J Med. 1990;89:554-560.
10. 12U), in chronic fatigue syndrome. Clin Infect Dis. 1994;18:S88-S95.
11. Steinberg P, McNutt BE, Marshall P, et al. Double-blind placebo-controlled study of the efficacy of oral terfenadine in the treatment of chronic fatigue syndrome. J Allergy Clin Immunol. 1996;97:119-126.
12. Kaslow JE, Rucker L, Onishi R. Liver extract-folic acid-cyanocobalamin vs placebo for chronic fatigue syndrome. Arch Intern Med. 1989;149:2501-2503.
13. Vercoulen JHM, SwaninkCMA, Zitman FG, et al. Randomized, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet. 1996;347:858-861.
14. Bou-Holaigah I, Rowe PC, Kan J, Calkins H. The relationship between neurally mediated hypotension and the chronic fatigue syndrome. JAMA. 1995;274:961-967.
15. Stewart AL, Hays RD, Ware JE Jr. The MOS Short-Form General Health Survey: reliability and validity in a patient population. Med Care. 1988;26:724-731.
16. Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988;54:1063-1070.
17. Jensen AR. Individual differences in the Hick paradigm. In: Vernon P, ed. Speed and Information Processing and Intelligence. Norwood, NJ: Ablex Publishing; 1987:101-175.
18. Marshall PS, Forstot M, Callieo A, Peterson PK, Schenck CH. Cognitive slowing and working memory difficulties in chronic fatigue syndrome. Psychosom Med. 1997;59:58-66.
19. Candito M, Krstulovic C, Sbirazzuoli V, Chambon P. Proposal for the standardization of the calibration method for the assay of plasma catecholamines. J Chromatogr. 1990;526:194-202.
20. Molzham M, Dissman TH, Halim S. Orthostatic changes of hemodynamics, renal function, plasma catecholamine and plasma renin concentration in normal and hypertensive man. Clin Sci. 1972;42:209-222.
21. Christenson NJ. Sympathetic nervous activity during exercise. Ann Rev Physiol. 1983;45:139-153.
22. Calkins H, Kan J, Rowe PC. Chronic fatigue syndrome and neurally mediated hypotension. JAMA. 1996;275:360.
23. Bou-Holaigah I, Rowe PC, Kan J, Calkins H. Response to upright tilt testing in 100 consecutive patients with chronic fatigue syndrome [abstract]. Circulation. 1995;92:1-414.
24. Freeman R, Komaroff AL. Does the chronic fatigue syndrome involve the autonomic nervous system? Am J Med. 1997;102:357-364.
25. Bentall RP, Wood GC, Marinam T, Dears C, Edwards RHT. A brief mental fatigue questionnaire. Br J Clin Psychol. 1993;32:375-379.
26. Wood C, Magnello ME, Sharpe MC. Fluctuations in perceived energy and mood among patients with chronic fatigue syndrome. J R Soc Med. 1992;85:195-198.
27. Marshall PS, Watson D, Steinberg P, et al. An assessment of cognitive function and mood in chronic fatigue syndrome. Biol Psychiatry. 1996;39:199-206.
28. Antonios TFT, MacGregor GA. Salt: more adverse effects. Lancet. 1996;348:250-251.